|Description||CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is also used for the treatment of rectal cancer and non-small cell lung cancer. It was developed by Daiichi Sankyo Company Limited. It is in clinic phase 2 with no progress.|
|Synonyms||Efatutazone dihydrochloride monohydrate;5-[[4-[[6-(4-Amino-3,5-dimethylphenoxy)-1-methylbenzimidazol-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione hydrate dihydrochloride;Inolitazone dihydrochloride monohydrate;(+/-)-2,4-Thiazolidinedione, 5-((4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl)methoxy)phenyl)methyl)-, dihydrochloride, monohydrate|
|Solubility||10 mM in DMSO|
|Application||CS-7017 monohydrate is a potential therapy for thyroid cancer and liposarcoma. It is also used for the treatment of rectal cancer and non-small cell lung cancer.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||CS-7017 monohydrate was developed by Daiichi Sankyo Company Limited. It is in clinic phase 2 with no progress.|
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...
ST247 is a selective and inverse peroxisome proliferator-activated receptor (PPAR)β/δ agonist with IC 50 value of 19 nm, 10-fold more potent than GSK0660 with I...
Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ.
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...
WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).
PPAR agonist 1
An agonist of PPAR α and PPAR γ
A potent, tyrosine-based peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC50 = 13 nM for murine receptor and 6.2 nM for human receptor in cell-ba...
PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...
MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...
Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...
INT 131 is a hypoglycemic agent, displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared...
The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coeffici...
Protopanaxatriol is a dammarane-type tetracyclic triterpene sapogenins found in ginseng (Panax ginseng) and in notoginseng (Panax pseudoginseng). It may have a ...
Pemafibrate is a Peroxisome proliferator-activated receptor alpha agonist. It can decrease the secretion of inflammatory markers without affecting cell prolifer...
GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.